

Bölüm 8

PREMATÜR EJAKÜLASYON: MEDİKAL VE CERRAHİ TEDAVİDE GÜNCEL BİLGİLER

Mehmet YILMAZ¹

GİRİŞ

Seksüel performans anksiyetesinin ağırlıklı parametresi prematür ejakülasyon (PE) olup prevalansı toplumsal ve tanımsal farklılıklar gölgesinde %4-75 gibi geniş bir aralıkta tariflenmektedir (1, 2).

PE terminolojisi erkek ya da kadının cinsel aktivitedeki tatmin sürecinin ejakülasyonunun erken oluşmasına bağlı bozulmasını ifade etmektedir. Erkeklerde görülen en sık cinsel fonksiyon bozukluğu olup yaklaşık %30 unun yaşamları boyunca bir noktada bu cinsel işlev bozukluğundan şikâyet edebileceği ihtimal dahilindedir (3).

TANIMLAMA:

PE “ejaculatio ante portas” ifadesi ile antik Yunan yazıtlarına kadar uzansa da medikal terminolojide ilk kez hızlı boşalma olgusu ile raporlandığı 1887 yılına kadar objektif kriterler ve kanıta dayalı ele alınamaması gibi nedenlerle kabul edilmiş bir tanımlamadan uzak kalmıştır (4, 5). Bu kriterlere uygun ilk kabul edilebilir klinik tanımlama ise literatüre Masters ve Johnson’un 1970 yılında tariflediği “Bir erkeğin cinsel ilişki girişimlerinin %50’ sinde partnerinin orgazma ulaşmasına yetecek kadar boşalmayı geciktirememesi” tanımı ile girmiştir (6).

Cinsel aktivitede, ejakülasyonun erteleme kabiliyetinin kaybına bağlı karşı tarafta cinsel tatminsizlik oluşumu olarak nitelenebilecek PE için çeşitli otoriteler ve komiteler kapsamlı tanımlamalar getirmiştir. Kapsamlı ve güncel yönüyle Uluslararası Cinsel Tıp Derneği (ISSM) in 2014 tarihli tanımı referans özellik taşımaktadır. ISSM’ in tanımladığı 3 kriter;

1. Yaşam boyu PE, ilk cinsel deneyimden itibaren vajinal penetrasyona izin vermeyecek kadar hızlı ya da penetrasyonu müteakiben en fazla bir dakika

¹ Uzm. Dr., Sağlık Bilimleri Üniversitesi Bağcılar Eğitim ve Araştırma Hastanesi, drmehmetyilmaz@yandex.com, ORCID iD: 0000-0002-5780-534X

uç kısma ulaşmasını önler (52). Literatürde tariflenen randomize kontrollü ve prospektif temelli çalışmalara bakıldığında net bir uygulama standardizasyonu olmadığı ancak çoklu noktaya 30 G enjektör ve ortalama 1 ml lik uygulamaların IELT süresini 3-5 kat artırdığı ve bu etkinin uzun takip sürecinde azalsa da devam ettiği ortaya konmuş. Ayrıca çalışmalar ciddi bir yan etki tariflemeyen (spontan gerileyen rahatsızlık, ekimoz ve papül oluşumu) cinsel doyum her iki taraf için de artmış bulundu (53-56).

Ejakülasyon sürecinin karmaşık patogenezinde en iyi ortaya konmuş periferik nörolojik olay bulbospongiöz kasın ritmik kontraksiyonunun BoNT ile blokajı sayesinde geciktirilebilmesidir. Literatürde farklı uygulama lokalizasyonları içerisinde bulbospongiöz kas, intraprostatik saha, frenilum, prepisyum ile glans penis ve intrakavernöz uygulamaları insan ve hayvan çalışmalarında yaklaşık 3 kat artmış IELT yanısıra minimal ve geri dönenilir yan etkilerle gösterilmiştir (57).

SONUÇ:

Günümüzde PE için onaylanmış tek tedavi dapoksetindir. Ancak PE' in karmaşık nörobiyolojisi ışığında ortaya konan yeni gelişmeler çok farklı tanı ve tedavi sahalarını araştırmacıların merakına açmış, böylece hem farmakoterapi hem de invaziv yaklaşım içeren yeni tedavi modaliteleri popüler hale gelmiştir. Konvansiyonel endikasyon dışı tedaviler serotonerjik ajanlar ile topikal anestezipler iken bugün özellikle Asya toplumundan Batı dünyasına alternatif tıp yöntemleri, farklı endikasyon dışı farmakoterapiler, iyi tanımlanan denervasyon cerrahileri ve minimal invaziv dolgu materyalleri/ nöro modülasyonlar endikasyon sahasını genişletmektedir. Karmaşık nörobiyolojik doğası aydınlatıldıkça medikal ajan araştırmaları ve girişimsel tedavi çalışmaları gelecek için küratif PE tedavisi umutlarımızı arttıracaktır.

KAYNAKÇA

1. El-Hamd MA, Saleh R, Majzoub A. Premature ejaculation: an update on definition and pathophysiology. *Asian J Androl.* 2019 Sep-Oct;21(5):425-432.
2. Althof SE, McMahon CG, Waldinger MD, et al. An Update of the International Society of Sexual Medicine's Guidelines for the Diagnosis and Treatment of Premature Ejaculation (PE). *Sex Med.* 2014 Jun;2(2):60-90. doi: 10.1002/sm2.28
3. Saitz TR, Serefoglu EC. The epidemiology of premature ejaculation. *Transl Androl Urol.* 2016;5(4):409-415.
4. Gross S. *Practical Treatise on Impotence and Sterility and Allied Disorders of the Male Sexual Organs.* Edinburg, YJ: Pentland; 1887.

5. Ateş E, Kazıcı HG. Premature ejaculation: current and future treatments. *Androl Bul* 2021;23:278–289<https://doi.org/10.24898/tandro.2021.58569>
6. Masters WH, Johnson VE. *Human sexual inadequacy*. London; Boston: Churchill; Little Brown, 1970.
7. Serefoglu EC, McMahon CG, Waldinger MD, et al. An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the Second International Society for Sexual Medicine Ad Hoc Committee for the Definition of Premature Ejaculation. *J Sex Med* 2014;2:41-59.
8. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5)*. Washington: American Psychiatric Association; 2013. p. 443–446.
9. Salonia A, Bettocchi C, Boeri L, et al. European Association of Urology guidelines on sexual and reproductive health—2021 update: male sexual dysfunction. *Eur Urol* 2021; 80:333-57.
10. Rowland DL. Psychological impact of premature ejaculation and barriers to its recognition and treatment. *Curr Med Res Opin*. 2011 Aug;27(8):1509-18.
11. Crowdis M, Leslie SW, Nazir S. Premature Ejaculation. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; May 30, 2023.
12. Shaeer O. The global online sexuality survey (GOSS): The United States of America in 2011 Chapter III--Premature ejaculation among English-speaking male Internet users. *J Sex Med* 2013;10:1882-8. 10.1111/jsm.12187
13. Son H, Song SH, Kim SW, et al. Self-reported premature ejaculation prevalence and characteristics in Korean young males: community-based data from an internet survey. *J Androl* 2010;31:540-6. 10.2164/jandrol.110.010355
14. Shaeer O, Shaeer K. The Global Online Sexuality Survey (GOSS): ejaculatory function, penile anatomy, and contraceptive usage among Arabic-speaking Internet users in the Middle East. *J Sex Med* 2012;9:425-33. 10.1111/j.1743-6109.2011.02338.x
15. Verze P, Arcaniolo D, Palmieri A, et al. Premature ejaculation among Italian men: prevalence and clinical correlates from an observational, non-interventional, cross-sectional, epidemiological study (IPER). *J Sex Med* 2018;6:193-202.
16. Serefoglu EC, Yaman O, Cayan S, et al. Prevalence of the complaint of ejaculating prematurely and the four premature ejaculation syndromes: results from the Turkish Society of Andrology Sexual Health Survey. *J Sex Med* 2011;8:540-548.
17. Zhang X, Gao J, Liu J, et al. Distribution and factors associated with four premature ejaculation syndromes in out patients complaining of ejaculating prematurely. *J Sex Med* 2013;10:1603-1611
18. Gao J, Zhang X, Su P, et al. Prevalence and factors associated with the complaint of premature ejaculation and the four premature ejaculation syndromes: a large observational study in China. *J Sex Med* 2013;10:1874-81. 10.1111/jsm.12180
19. Raveendran AV, Agarwal A. Premature ejaculation - current concepts in the management: A narrative review. *Int J Reprod Biomed*. 2021;19(1):5-22. Published 2021 Jan 25. doi:10.18502/ijrm.v19i1.8176
20. Waldinger MD. Recent advances in the classification, neurobiology and treatment of premature ejaculation. *Adv Psychosom Med* 2008; 29: 50–69.
21. Peeters M, Giuliano F. Central neurophysiology and dopaminergic control of ejaculation. *Neurosci Biobehav Rev*. 2008;32(3):438-453. doi:10.1016/j.neubiorev.2007.07.013

22. Ferrari F, Giuliani D. Behavioral effects induced by the dopamine D3 agonist 7-OH-DPAT in sexually-active and -inactive male rats. *Neuropharmacology*. 1996; 35, 279–284.
23. Clement P, Bernabe J, Denys P, et al. Ejaculation induced by i.c.v. injection of the preferential dopamine D(3) receptor agonist 7-hydroxy-2-(di-N-propylamino)tetralin in anesthetized rats. *Neuroscience*. 2007. 145, 605–610.
24. Arletti R, Bazzani C, Castelli M, et al. Oxytocin improves male copulatory performance in rats. *Horm Behav*. 1985; 19:14–20.
25. Argiolas A, Collu M, Gessa GL, et al. The oxytocin antagonist d(CH2)5Tyr(-Me)-Orn8-vasotocin inhibits male copulatory behaviour in rats. *Eur J Pharmacol*. 1988;149:389–392.
26. Clément P, Bernabé J, Compagnie S, et al. Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. *Br J Pharmacol*. 2013 Aug;169(7):1477-85. doi: 10.1111/bph.12198
27. Martin-Tuite P, Shindel AW. Management Options for Premature Ejaculation and Delayed Ejaculation in Men. *Sex Med Rev*. 2020;8(3):473-485. doi:10.1016/j.sxmr.2019.09.002
28. Zhang D, Cheng Y, Wu K, Ma Q, Jiang J, Yan Z. Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis. *BMC Urol*. 2019 Jan 03;19(1):2.
29. Kam SC, Han DH, Lee SW. The diagnostic value of the premature ejaculation diagnostic tool and its association with intravaginal ejaculatory latency time. *J Sex Med*. 2011;8:865–71
30. McCabe MP, Sharlip ID, Atalla E, et al. Definitions of Sexual Dysfunctions in Women and Men: A Consensus Statement From the Fourth International Consultation on Sexual Medicine 2015. *J Sex Med*. 2016 Feb;13(2):135-43.
31. Waldinger MD. The pathophysiology of lifelong premature ejaculation. *Transl Androl Urol*. 2016 Aug;5(4):424-33. doi: 10.21037/tau.2016.06.04.
32. Bukhari SR. Psycho, Pharmaco and Sex therapy for the treatment of Premature Ejaculation. *Pak J Med Sci*. 2022 Nov-Dec;38(8):2350-2355. doi: 10.12669/pjms.38.8.5217.
33. Xin ZC, Zhu YC, Yuan YM, et al. Current therapeutic strategies for premature ejaculation and future perspectives. *Asian J Androl* 2011;13:550–7.
34. Bao B, Shang J, Wang J, et al. Efficacy and safety of behavioral therapy for premature ejaculation: Protocol for a systematic review. *Medicine (Baltimore)*. 2019 Jan;98(3):e14056. doi: 10.1097/MD.00000000000014056
35. McMahon CG, Althof SE, Kaufman JM, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. *J Sex Med* 2011;8:524-539
36. Kim YH, Bahng M-Y, Lim H-S, et al. Pharmacokinetic interaction between udenafil and dapoxetine: a randomized, open-labeled crossover study in healthy male volunteers. *Drug Des Devel Ther* 2015;9:1209-1216.
37. Mirone V, Arcaniolo D, Rivas D, et al. Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: the PAUSE study. *Eur Urol* 2014;65:733-739.
38. Desai C. Meyler's side effects of drugs: The international encyclopedia of adverse drug reactions and interactions. *Indian J Pharmacol*. 2016 Mar-Apr;48(2):224. PMID: PMC4825447.

39. Moreland AJ, Makela EH. Selective serotonin-reuptake inhibitors in the treatment of premature ejaculation. *Ann Pharmacother.* 2005;39(7-8):1296-1301. doi:10.1345/ap-h.1E069
40. Wu PC, Hung CS, Kang YN, et al. Tolerability and Optimal Therapeutic Dosage of Clomipramine for Premature Ejaculation: A Systematic Review and Meta-Analysis. *Sex Med.* 2021;9(1):100283. doi:10.1016/j.esxm.2020.10.011
41. Marcou TA, Marque S, Mazoit JX, Benhamou D. The median effective dose of tramadol and morphine for postoperative patients: A study of interactions. *Anesthesia And Analgesia,* 2005; 100(2), 469–474. doi: 10.1213/01.Ane.0000142121.24052.25
42. Tan H, Zhou Z, Cui Y, et al. A systematic review and meta-analysis of randomized controlled trials of “on-demand” use of tramadol vs “on-demand” use of paroxetine in the management of patients with premature ejaculation. *Int J Clin Pract.* 2021;75(11):e14825. doi:10.1111/ijcp.14825
43. Mitsogiannis I, Dellis A, Papatsoris A, Moussa M. An up-to-date overview of the pharmacotherapeutic options for premature ejaculation. *Expert Opin Pharmacother.* 2022;23(9):1043-1050. doi:10.1080/14656566.2022.2035361
44. Bhat GS, Shastry A. Effectiveness of “on demand” silodosin in the treatment of premature ejaculation in patients dissatisfied with dapoxetine: a randomized control study. *Cent European J Urol.* 2016;69(3):280–284. doi: 10.5173/ceju.2016.843
45. Jindan L, Xiao W, Liping X. Evolving Role of Silodosin for the Treatment of Urological Disorders - A Narrative Review. *Drug Des Devel Ther.* 2022 Aug 26;16:2861-2884. doi: 10.2147/DDDT.S373659. PMID: 36051157; PMCID: PMC9427207.
46. McMahan C, Althof S, Rosen R, et al. The Oxytocin Antagonist Cligosiban Prolongs Intravaginal Ejaculatory Latency and Improves Patient-Reported Outcomes in Men with Lifelong Premature Ejaculation: Results of a Randomized, Double-Blind, Placebo-Controlled Proof-of- Concept Trial (PEPIX). *J Sex Med* 2019;16:1178–87
47. Tuken M, Kiremit MC, Serefoglu EC. On-demand Modafinil Improves Ejaculation Time and Patient-reported Outcomes in Men With Lifelong Premature Ejaculation. *Urology.* 2016;94:139-142. doi:10.1016/j.urology.2016.04.036
48. Abu El-Hamd M. Effectiveness and tolerability of lidocaine 5% spray in the treatment of lifelong premature ejaculation patients: a randomized single-blind placebo-controlled clinical trial [published correction appears in *Int J Impot Res.* 2020 May;32(3):367]. *Int J Impot Res.* 2021;33(1):96-101. doi:10.1038/s41443-019-0225-9
49. Butcher MJ, Zubert T, Christiansen K, et al. Topical Agents for Premature Ejaculation: A Review. *Sex Med Rev.* 2020;8(1):92-99. doi:10.1016/j.sxmr.2019.03.003
50. Choi HK, Jung GW, Moon KH, et al. Clinical study of SS-cream in patients with lifelong premature ejaculation. *Urology* 2000; 55:257-261.
51. Moon du G. Is there a place for surgical treatment of premature ejaculation? *Transl Androl Urol.* 2016 Aug;5(4):502-7. doi: 10.21037/tau.2016.05.06.
52. Schifano N, Capogrosso P, Antonini G, et al. The Application of Hyaluronic Acid Injections in Functional and Aesthetic Andrology: A Narrative Review. *Gels.* 2023;9(2):118. Published 2023 Feb 1. doi:10.3390/gels9020118
53. Abdallah H, Abdelnasser T, Hosny H, et al. Treatment of premature ejaculation by glans penis augmentation using hyaluronic acid gel: A pilot study. *Andrologia* 2011; 44, 650–653.

54. Shebl SE, Ali S, Shokr M. Hyaluronic acid injection in the glans penis for the treatment of refractory premature ejaculation: A prospective, controlled study. *Andrologia* 2021; 53, e14084
55. Littara A, Palmieri B, Rottigni V et al. A clinical study to assess the effectiveness of a hyaluronic acid-based procedure for treatment of premature ejaculation. *Int. J. Impot. Res.* 2013; 25, 117–120.
56. Alahwany A, Ragab MW, Zaghoul A, et al. Hyaluronic acid injection in glans penis for treatment of premature ejaculation: A randomized controlled cross-over study. *Int. J. Impot. Res.* 2019; 31, 348–355
57. Reddy AG, Dick BP, Natale C, et al. Application of Botulinum Neurotoxin in Male Sexual Dysfunction: Where Are We Now?. *Sex Med Rev.* 2021;9(2):320-330. doi:10.1016/j.sxmr.2020.05.004